Pancreas

Endoscopy. 2022;54(1):4–12

Chen YI, Chatterjee A, Berger R, Kanber Y, Wyse J, Lam E, Gan I, Auger M, Kenshil S, Telford J, Donnellan F, Quinlan J, Lutzak G, Alshamsi F, Parent J, Waschke K, Alghamdi A, Barkun J, Metrakos P, Chaudhury P, Martel M, Dorreen A, Candido K, Miller C, Adam V, Barkun A, Zogopoulos G, Wong C

Endoscopic ultrasound (EUS)-guided fine needle biopsy alone vs. EUS-guided fine needle aspiration with rapid onsite evaluation in pancreatic lesions: A multicenter randomized trial


Background: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is the standard in the diagnosis of solid pancreatic lesions, in particular when combined with rapid onsite evaluation of cytopathology (ROSE). More recently, a fork-tip needle for core biopsy (FNB) has been shown to be associated with excellent diagnostic yield. EUS-FNB alone has, however, not been compared with EUS-FNA + ROSE in a large clinical trial. The aim of this trial was to compare EUS-FNB alone to EUS-FNA + ROSE in solid pancreatic lesions.
Methods: A multicenter, non-inferiority, randomized controlled trial involving 7 centers was performed. Solid pancreatic lesions referred for EUS were considered for inclusion. The primary end point was diagnostic accuracy. Secondary end points included sensitivity/specificity, mean number of needle passes, and cost.
Results: 235 patients were randomized: 115 EUS-FNB alone and 120 EUS-FNA + ROSE. Overall, 217 patients had malignant histology. The diagnostic accuracy for malignancy of EUS-FNB alone was non-inferior to EUS-FNA + ROSE at 92.2% (95% confidence interval [CI]: 86.6–96.9%) and 93.3% (95% CI: 88.8–97.9%), respectively (p = 0.72). Diagnostic sensitivity for malignancy was 92.5% (95% CI: 85.7–96.7%) for EUS-FNB alone versus 96.5% (95% CI: 93.0–98.6%) for EUS-FNA + ROSE (p = 0.46), while specificity was 100% in both. Adequate histological yield was obtained in 87.5% of the EUS-FNB samples. The mean number of needle passes and procedure time favored EUS-FNB alone (2.3 ± 0.6 passes vs. 3.0 ± 1.1 passes, p < 0.001, and 19.3 ± 8.0 vs. 22.7 ± 10.8 minutes, p = 0.008). EUS-FNB alone cost on average 45 US dollars more than EUS-FNA + ROSE.

Conclusion: Endoscopic ultrasound (EUS)-guided fine needle biopsy alone is non-inferior to EUS-guided fine needle aspiration combined with rapid onsite evaluation of cytopathology and is associated with fewer needle passes, shorter procedure time, and excellent histological yield at comparable cost.

Dr. Y.-I Chen, Division of Gastroenterology and Hepatology, McGill University Health Center, Montreal, QC, Canada,
E-Mail: yen-i.chen@mcgill.ca

DOI: DOI: 10.1055/a-1375-9775

Back to overview

this could be of interest:

Changes in metabolic syndrome status are associated with altered risk of pancreatic cancer: A nationwide cohort study

Gastroenterology. 2022;162(2):509–20.e7

Late-stage pancreatic cancer detected during high-risk individual surveillance: A systematic review and meta-analysis

Gastroenterology. 2022;162(3):786–98

More articles on the topic